This regimen is recommended for patients with good performance status irrespective of tumor PD-L1 tumor proportion score (TPS), except in the presence of an oncogene predicting lack of benefit or other contraindication to PD-1/PD-L1 inhibitor therapy. The gene discussed is CD274; the disease is neoplasm.